Isolated DNA molecules (a) have any of the sequences (all reproduced) (1; 226 nucleotides (nt)), a lovastatin probe; (2; 9818 nt), mkA; (3; 8081 nt), mkB; (4; 1717 nt), mkC; (5; 792 nt), mkD; (6; 1228 nt), mkE; (7; 1425 nt), mkF; (8; 3356 nt), mkG; (9; 1464 nt), mkH; or (10; 2148 nt), mkI; or (b) are sequences that hybridize to (a) under stringent conditions. - Independent claims are also included for the following: - (1) shuttle vector containing the new molecules; - (2) isolated DNA sequences (all reproduced) that are the cDNAs corresponding to genomic sequences (2)-(10); - (3) shuttle vectors that contain the cDNA of (2); - (4) cells transformed with at least one sequence (2)-(10) or the new cDNA; - (5) method for increasing production of lovastatin (I) by transforming a (I)-producing cell with at least one of (2)-(10) or the corresponding cDNA; - (6) method for producing an inhibitor (X) of HMG-CoA reductase by culturing an (X)-producing cell that has been transformed with any of (2), (3), (6) and (7), or the corresponding cDNA; - (7) isolated DNA that (i) encodes the proteins (all sequences reproduced) (11; 3075 amino acids (aa)); (12; 2547 aa); (13; 524 aa); (14; 263 aa); (15; 360 aa); (16; 413 aa); (28; 1052 aa); (17; 455 aa); or (18; 543 aa) or (ii) can hybridize to (i) under stringent conditions; and - (8) expression vector that contains the DNA of (7). - ACTIVITY - Hypotensive; Antidiabetic; Antilipemic; Antifungal. - No details of tests for these activities are given. - MECHANISM OF ACTION - HMG-Co reductase Inhibitor.
專利性質
發明
技術摘要-中文
Isolated DNA molecules (a) have any of the sequences (all reproduced) (1; 226 nucleotides (nt)), a lovastatin probe; (2; 9818 nt), mkA; (3; 8081 nt), mkB; (4; 1717 nt), mkC; (5; 792 nt), mkD; (6; 1228 nt), mkE; (7; 1425 nt), mkF; (8; 3356 nt), mkG; (9; 1464 nt), mkH; or (10; 2148 nt), mkI; or (b) are sequences that hybridize to (a) under stringent conditions. - Independent claims are also included for the following: - (1) shuttle vector containing the new molecules; - (2) isolated DNA sequences (all reproduced) that are the cDNAs corresponding to genomic sequences (2)-(10); - (3) shuttle vectors that contain the cDNA of (2); - (4) cells transformed with at least one sequence (2)-(10) or the new cDNA; - (5) method for increasing production of lovastatin (I) by transforming a (I)-producing cell with at least one of (2)-(10) or the corresponding cDNA; - (6) method for producing an inhibitor (X) of HMG-CoA reductase by culturing an (X)-producing cell that has been transformed with any of (2), (3), (6) and (7), or the corresponding cDNA; - (7) isolated DNA that (i) encodes the proteins (all sequences reproduced) (11; 3075 amino acids (aa)); (12; 2547 aa); (13; 524 aa); (14; 263 aa); (15; 360 aa); (16; 413 aa); (28; 1052 aa); (17; 455 aa); or (18; 543 aa) or (ii) can hybridize to (i) under stringent conditions; and - (8) expression vector that contains the DNA of (7). - ACTIVITY - Hypotensive; Antidiabetic; Antilipemic; Antifungal. - No details of tests for these activities are given. - MECHANISM OF ACTION - HMG-Co reductase Inhibitor.
Isolated DNA molecules (a) have any of the sequences (all reproduced) (1; 226 nucleotides (nt)), a lovastatin probe; (2; 9818 nt), mkA; (3; 8081 nt), mkB; (4; 1717 nt), mkC; (5; 792 nt), mkD; (6; 1228 nt), mkE; (7; 1425 nt), mkF; (8; 3356 nt), mkG; (9; 1464 nt), mkH; or (10; 2148 nt), mkI; or (b) are sequences that hybridize to (a) under stringent conditions. - Independent claims are also included for the following: - (1) shuttle vector containing the new molecules; - (2) isolated DNA sequences (all reproduced) that are the cDNAs corresponding to genomic sequences (2)-(10); - (3) shuttle vectors that contain the cDNA of (2); - (4) cells transformed with at least one sequence (2)-(10) or the new cDNA; - (5) method for increasing production of lovastatin (I) by transforming a (I)-producing cell with at least one of (2)-(10) or the corresponding cDNA; - (6) method for producing an inhibitor (X) of HMG-CoA reductase by culturing an (X)-producing cell that has been transformed with any of (2), (3), (6) and (7), or the corresponding cDNA; - (7) isolated DNA that (i) encodes the proteins (all sequences reproduced) (11; 3075 amino acids (aa)); (12; 2547 aa); (13; 524 aa); (14; 263 aa); (15; 360 aa); (16; 413 aa); (28; 1052 aa); (17; 455 aa); or (18; 543 aa) or (ii) can hybridize to (i) under stringent conditions; and - (8) expression vector that contains the DNA of (7). - ACTIVITY - Hypotensive; Antidiabetic; Antilipemic; Antifungal. - No details of tests for these activities are given. - MECHANISM OF ACTION - HMG-Co reductase Inhibitor.
專利性質
發明
技術摘要-中文
Isolated DNA molecules (a) have any of the sequences (all reproduced) (1; 226 nucleotides (nt)), a lovastatin probe; (2; 9818 nt), mkA; (3; 8081 nt), mkB; (4; 1717 nt), mkC; (5; 792 nt), mkD; (6; 1228 nt), mkE; (7; 1425 nt), mkF; (8; 3356 nt), mkG; (9; 1464 nt), mkH; or (10; 2148 nt), mkI; or (b) are sequences that hybridize to (a) under stringent conditions. - Independent claims are also included for the following: - (1) shuttle vector containing the new molecules; - (2) isolated DNA sequences (all reproduced) that are the cDNAs corresponding to genomic sequences (2)-(10); - (3) shuttle vectors that contain the cDNA of (2); - (4) cells transformed with at least one sequence (2)-(10) or the new cDNA; - (5) method for increasing production of lovastatin (I) by transforming a (I)-producing cell with at least one of (2)-(10) or the corresponding cDNA; - (6) method for producing an inhibitor (X) of HMG-CoA reductase by culturing an (X)-producing cell that has been transformed with any of (2), (3), (6) and (7), or the corresponding cDNA; - (7) isolated DNA that (i) encodes the proteins (all sequences reproduced) (11; 3075 amino acids (aa)); (12; 2547 aa); (13; 524 aa); (14; 263 aa); (15; 360 aa); (16; 413 aa); (28; 1052 aa); (17; 455 aa); or (18; 543 aa) or (ii) can hybridize to (i) under stringent conditions; and - (8) expression vector that contains the DNA of (7). - ACTIVITY - Hypotensive; Antidiabetic; Antilipemic; Antifungal. - No details of tests for these activities are given. - MECHANISM OF ACTION - HMG-Co reductase Inhibitor.
Cholesterol inhibitor produced by Monascus, monacolin k, is a secondary metabolite of polyketides. The invention provides probes specific to monacolin k biosynthesis gene cluster. BAC clones having putative monacolin k gene cluster were screened from BAC (bacterial artificial chromosome) library, and sequencing and annotation were performed on these clones. The results show that 2 polyketide synthase (PKS) genes and 7 regulatory genes related to monacolin k synthesis were obtained. Full-length cDNAs of these genes were then obtained by RT-PCR and cloned to expression vectors for the expression of these genes. _x000D__x000D_
技術摘要-中文: Cholesterol inhibitor produced by Monascus, monacolin k, is a secondary metabolite of polyketides. The invention provides probes specific to monacolin k biosynthesis gene cluster. BAC clones having putative monacolin k gene cluster were screened from BAC (bacterial artificial chromosome) library, and sequencing and annotation were performed on these clones. The results show that 2 polyketide synthase (PKS) genes and 7 regulatory genes related to monacolin k synthesis were obtained. Full-length cDNAs of these genes were then obtained by RT-PCR and cloned to expression vectors for the expression of these genes. _x000D__x000D_
Cholesterol inhibitor produced by Monascus, monacolin k, is a secondary metabolite of polyketides. The invention provides probes specific to monacolin k biosynthesis gene cluster. BAC clones having putative monacolin k gene cluster were screened from BAC (bacterial artificial chromosome) library, and sequencing and annotation were performed on these clones. The results show that 2 polyketide synthase (PKS) genes and 7 regulatory genes related to monacolin k synthesis were obtained. Full-length cDNAs of these genes were then obtained by RT-PCR and cloned to expression vectors for the expression of these genes.
技術摘要-中文: Cholesterol inhibitor produced by Monascus, monacolin k, is a secondary metabolite of polyketides. The invention provides probes specific to monacolin k biosynthesis gene cluster. BAC clones having putative monacolin k gene cluster were screened from BAC (bacterial artificial chromosome) library, and sequencing and annotation were performed on these clones. The results show that 2 polyketide synthase (PKS) genes and 7 regulatory genes related to monacolin k synthesis were obtained. Full-length cDNAs of these genes were then obtained by RT-PCR and cloned to expression vectors for the expression of these genes.
Isolated DNA molecules (a) have any of the sequences (all reproduced) (1; 226 nucleotides (nt)), a lovastatin probe; (2; 9818 nt), mkA; (3; 8081 nt), mkB; (4; 1717 nt), mkC; (5; 792 nt), mkD; (6; 1228 nt), mkE; (7; 1425 nt), mkF; (8; 3356 nt), mkG; (9; 1464 nt), mkH; or (10; 2148 nt), mkI; or (b) are sequences that hybridize to (a) under stringent conditions. - Independent claims are also included for the following: - (1) shuttle vector containing the new molecules; - (2) isolated DNA sequences (all reproduced) that are the cDNAs corresponding to genomic sequences (2)-(10); - (3) shuttle vectors that contain the cDNA of (2); - (4) cells transformed with at least one sequence (2)-(10) or the new cDNA; - (5) method for increasing production of lovastatin (I) by transforming a (I)-producing cell with at least one of (2)-(10) or the corresponding cDNA; - (6) method for producing an inhibitor (X) of HMG-CoA reductase by culturing an (X)-producing cell that has been transformed with any of (2), (3), (6) and (7), or the corresponding cDNA; - (7) isolated DNA that (i) encodes the proteins (all sequences reproduced) (11; 3075 amino acids (aa)); (12; 2547 aa); (13; 524 aa); (14; 263 aa); (15; 360 aa); (16; 413 aa); (28; 1052 aa); (17; 455 aa); or (18; 543 aa) or (ii) can hybridize to (i) under stringent conditions; and - (8) expression vector that contains the DNA of (7). - ACTIVITY - Hypotensive; Antidiabetic; Antilipemic; Antifungal. - No details of tests for these activities are giv
技術摘要-中文: Isolated DNA molecules (a) have any of the sequences (all reproduced) (1; 226 nucleotides (nt)), a lovastatin probe; (2; 9818 nt), mkA; (3; 8081 nt), mkB; (4; 1717 nt), mkC; (5; 792 nt), mkD; (6; 1228 nt), mkE; (7; 1425 nt), mkF; (8; 3356 nt), mkG; (9; 1464 nt), mkH; or (10; 2148 nt), mkI; or (b) are sequences that hybridize to (a) under stringent conditions. - Independent claims are also included for the following: - (1) shuttle vector containing the new molecules; - (2) isolated DNA sequences (all reproduced) that are the cDNAs corresponding to genomic sequences (2)-(10); - (3) shuttle vectors that contain the cDNA of (2); - (4) cells transformed with at least one sequence (2)-(10) or the new cDNA; - (5) method for increasing production of lovastatin (I) by transforming a (I)-producing cell with at least one of (2)-(10) or the corresponding cDNA; - (6) method for producing an inhibitor (X) of HMG-CoA reductase by culturing an (X)-producing cell that has been transformed with any of (2), (3), (6) and (7), or the corresponding cDNA; - (7) isolated DNA that (i) encodes the proteins (all sequences reproduced) (11; 3075 amino acids (aa)); (12; 2547 aa); (13; 524 aa); (14; 263 aa); (15; 360 aa); (16; 413 aa); (28; 1052 aa); (17; 455 aa); or (18; 543 aa) or (ii) can hybridize to (i) under stringent conditions; and - (8) expression vector that contains the DNA of (7). - ACTIVITY - Hypotensive; Antidiabetic; Antilipemic; Antifungal. - No details of tests for these activities are giv
Isolated DNA molecules (a) have any of the sequences (all reproduced) (1; 226 nucleotides (nt)), a lovastatin probe; (2; 9818 nt), mkA; (3; 8081 nt), mkB; (4; 1717 nt), mkC; (5; 792 nt), mkD; (6; 1228 nt), mkE; (7; 1425 nt), mkF; (8; 3356 nt), mkG; (9; 1464 nt), mkH; or (10; 2148 nt), mkI; or (b) are sequences that hybridize to (a) under stringent conditions. - Independent claims are also included for the following: - (1) shuttle vector containing the new molecules; - (2) isolated DNA sequences (all reproduced) that are the cDNAs corresponding to genomic sequences (2)-(10); - (3) shuttle vectors that contain the cDNA of (2); - (4) cells transformed with at least one sequence (2)-(10) or the new cDNA; - (5) method for increasing production of lovastatin (I) by transforming a (I)-producing cell with at least one of (2)-(10) or the corresponding cDNA; - (6) method for producing an inhibitor (X) of HMG-CoA reductase by culturing an (X)-producing cell that has been transformed with any of (2), (3), (6) and (7), or the corresponding cDNA; - (7) isolated DNA that (i) encodes the proteins (all sequences reproduced) (11; 3075 amino acids (aa)); (12; 2547 aa); (13; 524 aa); (14; 263 aa); (15; 360 aa); (16; 413 aa); (28; 1052 aa); (17; 455 aa); or (18; 543 aa) or (ii) can hybridize to (i) under stringent conditions; and - (8) expression vector that contains the DNA of (7). - ACTIVITY - Hypotensive; Antidiabetic; Antilipemic; Antifungal. - No details of tests for these activities are giv
技術摘要-中文: Isolated DNA molecules (a) have any of the sequences (all reproduced) (1; 226 nucleotides (nt)), a lovastatin probe; (2; 9818 nt), mkA; (3; 8081 nt), mkB; (4; 1717 nt), mkC; (5; 792 nt), mkD; (6; 1228 nt), mkE; (7; 1425 nt), mkF; (8; 3356 nt), mkG; (9; 1464 nt), mkH; or (10; 2148 nt), mkI; or (b) are sequences that hybridize to (a) under stringent conditions. - Independent claims are also included for the following: - (1) shuttle vector containing the new molecules; - (2) isolated DNA sequences (all reproduced) that are the cDNAs corresponding to genomic sequences (2)-(10); - (3) shuttle vectors that contain the cDNA of (2); - (4) cells transformed with at least one sequence (2)-(10) or the new cDNA; - (5) method for increasing production of lovastatin (I) by transforming a (I)-producing cell with at least one of (2)-(10) or the corresponding cDNA; - (6) method for producing an inhibitor (X) of HMG-CoA reductase by culturing an (X)-producing cell that has been transformed with any of (2), (3), (6) and (7), or the corresponding cDNA; - (7) isolated DNA that (i) encodes the proteins (all sequences reproduced) (11; 3075 amino acids (aa)); (12; 2547 aa); (13; 524 aa); (14; 263 aa); (15; 360 aa); (16; 413 aa); (28; 1052 aa); (17; 455 aa); or (18; 543 aa) or (ii) can hybridize to (i) under stringent conditions; and - (8) expression vector that contains the DNA of (7). - ACTIVITY - Hypotensive; Antidiabetic; Antilipemic; Antifungal. - No details of tests for these activities are giv